Sugi Predict

Sugi Predict / Compounds / SCHEMBL2138123

SCHEMBL2138123

SCHEMBL2138123

COc1cc2c(Nc3c(F)cc(Cl)cc3F)ncnc2cc1O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 15/20 0.69
▸ RET P07949 11/20 0.69
▸ KIF5B P33176 11/20 0.69
▸ EGFR P00533 6/20 0.62
▸ FLT1 P17948 5/20 0.60
▸ FLT4 P35916 4/20 0.60
▸ FGFR1 P11362 4/20 0.60
▸ RIPK2 O43353 1/20 0.60
▸ NOD1 Q9Y239 1/20 0.60
▸ EPHB2 P29323 1/20 0.60
▸ RAF1 P04049 2/20 0.57
▸ BRAF P15056 2/20 0.57
▸ AURKA O14965 1/20 0.57
▸ ERBB2 P04626 1/20 0.57
▸ INSR P06213 1/20 0.57
▸ FBP1 P09467 1/20 0.57
▸ PDGFRB P09619 1/20 0.57
▸ CLK1 P49759 1/20 0.57
▸ EPHB4 P54760 1/20 0.57
▸ TEK Q02763 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7209985 0.89 KDR (0.70) KDRRETKIF5BEGFRFLT1
SCHEMBL2138034 0.88 KDR (0.61) KDRRETKIF5BEGFRFLT1
SCHEMBL1467058 0.85 KDR (0.83) KDRRETKIF5BEGFRFLT1
SCHEMBL3238800 0.83 EGFR (0.83) KDRRETKIF5BEGFRFLT4
SCHEMBL16760473 0.81 RET (1.00) KDRRETKIF5BEGFRFLT1
SCHEMBL2139115 0.79 KDR (0.66) KDRRETKIF5BEGFRFLT1
SCHEMBL19220799 0.79 KDR (0.73) KDRRETKIF5BEGFRFLT1
SCHEMBL16760438 0.79 RET (1.00) KDRRETKIF5BEGFRFLT1
SCHEMBL30124192 0.78 EGFR (0.83) KDRRETKIF5BEGFRFLT4
SCHEMBL29679736 0.78 EGFR (0.83) KDRRETKIF5BEGFRFLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210276972-A1 Quinazoline Derivatives as VEGF Inhibitors GENZYME CORPORATION (US) 2021-09-09 — — US disclosed
US-20200262811-A1 Quinazoline Derivatives as VEGF Inhibitors GENZYME CORPORATION (US) 2020-08-20 — — US disclosed
US-10457664-B2 Quinazoline derivatives as VEGF inhibitors GENZYME CORPORATION (US) 2019-10-29 — — US disclosed
US-20190002433-A1 Quinazoline Derivatives as VEGF Inhibitors GENZYME CORPORATION (US) 2019-01-03 — — US disclosed
US-20180099946-A1 Quinazoline Derivatives as VEGF Inhibitors GENZYME CORPORATION (US) 2018-04-12 — — US disclosed
US-20160130249-A1 Quinazoline Derivatives as VEGF Inhibitors ASTRAZENECA AB (SE) 2016-05-12 — — US disclosed
US-9040548-B2 Quinazoline derivatives as VEGF inhibitors ASTRAZENECA AB (SE) 2015-05-26 — — US disclosed
US-20140121228-A1 Quinazoline Derivatives as VEGF Inhibitors ASTRAZENECA AB (SE) 2014-05-01 — — US disclosed
US-8642608-B2 Quinazoline derivatives as VEGF inhibitors ASTRAZENECA AB (SE) 2014-02-04 — — US disclosed
US-20110065736-A1 QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS ASTRAZENECA AB (SE) 2011-03-17 — — US disclosed
EP-1676845-B1 New quinazoline derivatives ASTRAZENECA AB (SE) 2008-06-11 — — EP disclosed
US-20070265286-A1 Quinazoline derivatives as VEGF inhibitors ASTRAZENECA AB 2007-11-15 — — US disclosed
US-7173038-B1 Quinazoline derivatives as VEGF inhibitors ASTRAZENECA AB (SE) 2007-02-06 — — US disclosed
EP-1676845-A1 New quinazoline derivatives AstraZeneca AB (SE) 2006-07-05 — — EP disclosed
EP-1244647-B1 QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS ASTRAZENECA AB (SE) 2006-06-21 — — EP disclosed
EP-1244647-A1 QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS AstraZeneca AB (SE) 2002-10-02 — — EP disclosed
WO-2001032651-A1 QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS ASTRAZENECA AB (SE) 2001-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180099946-A1 Quinazoline Derivatives as VEGF Inhibitors FLT4, FLT1, KDR KDR 3/4885RET 503/4885KIF5B 2509/4885
US-20210276972-A1 Quinazoline Derivatives as VEGF Inhibitors FLT1, FLT4, KDR KDR 3/4885RET 624/4885KIF5B 2589/4885
US-20110065736-A1 QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS FLT1, FLT4, KDR KDR 3/4885RET 526/4885KIF5B 2469/4885
US-10457664-B2 Quinazoline derivatives as VEGF inhibitors FLT1, FLT4, KDR KDR 3/4885RET 509/4885KIF5B 2441/4885
US-20070265286-A1 Quinazoline derivatives as VEGF inhibitors FLT1, FLT4, KDR KDR 3/4885RET 526/4885KIF5B 2469/4885
US-20160130249-A1 Quinazoline Derivatives as VEGF Inhibitors FLT1, FLT4, KDR KDR 3/4885RET 446/4885KIF5B 2463/4885
US-20140121228-A1 Quinazoline Derivatives as VEGF Inhibitors FLT4, FLT1, KDR KDR 3/4885RET 583/4885KIF5B 2900/4885
US-20200262811-A1 Quinazoline Derivatives as VEGF Inhibitors FLT1, FLT4, KDR KDR 3/4885RET 446/4885KIF5B 2463/4885
US-20190002433-A1 Quinazoline Derivatives as VEGF Inhibitors FLT1, FLT4, KDR KDR 3/4885RET 509/4885KIF5B 2441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.